Supplementary material

- Figure 1 MEDLINE search strategy
- Figure 2 Funnel plots for tocilizumab outcomes
- Figure 3 Tocilizumab forest plot for mortality risk ratios RCTs only
- Figure 4 All agents forest plot for ordinal outcomes
- Figure 5 All agents forest plot for mean duration of hospitalisation
- Figure 6 All agents forest plot for mortality adjusted hazard ratios
- Figure 7 All agents forest plot for mortality risk ratios
- Figure 8 Anakinra mortality risk ratios (RR) forest plot
- Figure 9 Currently registered clinical trials
- Table 1 Characteristics of included studies
- Table 2 Patient characteristics and study outcomes
- Table 3(a-c) Risk of bias assessments
- Table 4 Primary outcome by individual study
- Table 5 Meta-regression values
- Table 6 GRADE rating

- 1. Respiratory Distress Syndrome, Adult/
- 2. SARS Virus/
- 3. Severe Acute Respiratory Syndrome/
- 4. severe acute respiratory distress syndrome*.mp.
- 5. Coronavirus Infections/
- 6. Coronavirus/
- 7. coronav*.mp.
- 8. covid*.mp.
- 9. SARS.mp.
- 10. Middle East Respiratory Syndrome


Coronavirus/

- 11. MERS.mp.
- 12. anakinra.mp.
- 13. kineret.mp.
- 14. tocilizumab.mp.
- 15. altizumab.mp.
- 16. actemra.mp.
- 17. roactemra.mp.
- 18. sarilumab.mp.
- 19. kevzara.mp.
- 20. siltuximab.mp.
- 21. sylvant.mp.
- 22. Interleukin 1 Receptor Antagonist

Protein/

- 23. anti-IL6.mp.
- 24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
- 25. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
- 26. 24 and 25


A. Ordinal outcomes




C. Mortality (adjusted hazard ratio)

Retrospective. Prospective. 0 0 Standard error Ŋ p = 0.082p = 0.16**Ø**0 0 0 0 0 0 0 Ó 2 Log hazard ratio


B. Duration of hospitalisation



D. Mortality (risk ratio).




Supplementary Figure 2: Funnel plots for outcomes evaluated in tocilizumab meta-analysis. A: ordinal outcomes, B: duration of hospitalisation, C: mortality (adjusted hazard ratio), D: mortality (risk ratio). Funnel plots presented separately for retrospective and prospective studies were applicable. Publication bias assessed using Egger's test, and p values presented next to funnel plot.




Supplementary Figure 3 – Tocilizumab mortality risk ratios (RR) forest plot for randomised controlled trials only. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N).


^{*} non peer-reviewed preprint studies # randomised controlled trials NR, not reported



Supplementary Figure 4 – All agents. Generalised odds ratios (OR) for ordinal outcome forest plot. Generalised OR shown for each study with 95% confidence interval and day at which ordinal outcome recorded. Sample sizes given for patients receiving intervention (n) alongside total included (N) in study. Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, Sa = sarilumab


^{*} non peer-reviewed preprint studies # randomised controlled trials






Supplementary Figure 5 – All studies mean duration of hospitalisation (days) forest plot. **A**: Mean duration of hospital stay. **B**: Mean difference compared with controls in duration of hospital stay. Effect sizes and associated 95% confidence intervals presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, Sa = sarilumab, Si = siltuximab.

^{*} non peer-reviewed preprint studies # randomised controlled trials




Supplementary Figure 6 – All studies, adjusted hazard ratios (HR) for overall mortality forest plot. Adjusted HRs with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included (N) in study. Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, Sa = sarilumab, Si = siltuximab.

^{*} non peer-reviewed preprint studies # randomised controlled trials NR, not reported



Supplementary Figure 7 - All agents, mortality risk ratios (RR) forest plot. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, Si = siltuximab, Sa = sarilumab * non peer-reviewed preprint studies # randomised controlled trials

NR, not reported



Supplementary Figure 8 – Anakinra mortality risk ratios (RR) forest plot. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies.

^{*} non peer-reviewed preprint studies

Estimated completion date (quarter)

Clinical Trial No.	Date Sample size 2020						20	21		2022			
Cimical manvo.	Date	Sample Size	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
NCT04315480	May-20	38	ì			-							
NCT04310228	May-20	150											
ChiCTR2000029765	May-20	188											
NCT04322188	May-20	50											
NCT04329650	May-20	100											
NCT04306705	May-20	120											
NCT04346355	May-20	398 ‡											
ChiCTR2000030196	May-20	60											
NCT04359667	Jun-20	30											
NCT04492501	Jul-20	600											
NCT04357860	Jul-20	120											
NCT04335305	Aug-20	24											
NCT04363736	Aug-20	100											
NCT04320615	Aug-20	450 ‡											
NCT04366232	Aug-20	54											
NCT04327388	Aug-20	421											
NCT04519385	Aug-20	69											
NCT04435717	Aug-20	78											
NCT04445272	Aug-20	500											
NCT04315298	Aug-20	1912											
NCT04462757	Sep-20	5											
NCT04364009	Sep-20	240											
NCT04372186	Sep-20	379 ‡											
NCT04335071	Oct-20	100											
NCT04345445	Oct-20	310											
NCT04356937	Oct-20	300 ‡											
NCT04332094	Oct-20	276											
NCT04361032	Oct-20	260											
NCT04560205	Oct-20	50											
NCT04377503	Dec-20	40											
NCT04409262	Dec-20	450											
NCT04386239	Dec-20	40											
NCT04330638	Dec-20	342*			Ш								
NCT04324021	Dec-20	54											
NCT04357808	Dec-20	30											
NCT04341584	Dec-20	240											
NCT04412291	Feb-21	120 *			П								
NCT04331795	Mar-21	332 ‡											
NCT04362111	Mar-21	30											
NCT04332913	Mar-21	30											
NCT04443881	Mar-21	180											
NCT04479358	Mar-21	332											
NCT04377750	May-21	500											
NCT04377659	May-21	40											
NCT04423042	Jun-21	30											
NCT04322773	Jun-21	200*											
NCT04486521	Jul-21	11000 *											
NCT04403685	Jul-21	129 †											
NCT04363853	Aug-21	200											
NCT04364009	Sep-21	240											
NCT04324073	Dec-21	239											
NCT04331808	Dec-21	228 ‡											
NCT04476979	Dec-21	120											
NCT04412772	Dec-21	300											
NCT04339712	Apr-22	40*											
NCT04359901	Apr-22	120											
NCT04357366	Apr-22	100											
NCT04370834	Apr-22	217 †											
NCT04361552	May-22	180 †											
NCT04424056	Nov-22	216 *											
NCT04317092	Dec-22	400 ‡											
NCT02735707	Dec-22	7100 *											
		. 200	1		.	·	

Tocilizumab
Siltuximab
Sarilumab
Anakinra

Supplementary Figure 9 - Currently registered clinical trials with estimated completion date presented per calendar year quarter. Clinical trials are stratified as per colour key. * same study investigating multiple immunomodulatory agents. † study has been terminated. ‡ results available

(last search 5th Oct)

Author, year	Study country	Centre	Study design	Dose	Participant criteria	Outcomes reported	Concomitant therapies
ANAKINRA							
Bakhair, 2020	Oman	single centre	Prospective with control	100mg S/C twice daily for 72h, then 100mg daily for 7 days	respiratory failure, bilateral lung infiltrates	mortality, ventilatory requirements	antibiotics
Huet, 2020	France	single centre	Prospective with control	100mg S/C twice daily for 72h, then 100mg daily for 7 days	respiratory failure, bilateral lung infiltrates	mortality, ventilatory requirement, laboratory biomarkers	hydroxychloroquine, antibiotics, IV methylprednisolone
Kooistra, 2020	Netherlands	multi- centre	Prospective with control	300mg IV then 100mg 6 hourly	IMV	mortality, ventilatory requirement, laboratory biomarkers	antivirals, hydroxychloroquine, corticosteroids
*Kyriazopoulou	Greece	multi- centre	Prospective	100mg S/C daily for 10 days	lung infiltrates and suPAR level ≥6ug/L	respiratory failure, mortality, SOFA score	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Cauchois, 2020	France	multi- centre	Retrospective	300mg IV daily for 5 days then tapered over 3 days	respiratory failure and CRP > 110mg/L	ventilatory requirement, laboratory biomarkers	hydroxychloroquine, antibiotics
Cavalli, 2020	Italy	single centre	Retrospective	10mg/kg/day IV	moderate-severe ARDS requiring CPAP and hyperinflammation	survival, ventilatory requirement, CRP	CPAP, hydroxychloroquine, lopinavir, ritonavir
Narain, 2020	USA	multi- centre	Retrospective	N/R	hyperinflammation	hospital mortality	hydroxychloroquine
SARILUMAB							
Benucci, 2020	Italy	single centre	Prospective	400mg IV repeated twice at 200mg at 48 hourly intervals	N/R	ventilatory requirement, laboratory biomarkers	hydroxychloroquine, azithromycin, antivirals
Della-Torre, 2020	Italy	single centre	Prospective with control	400mg IV	radiological bilateral lung infiltrates and hyperinflammation	overall survival, ventilatory requirements	hydroxychloroquine, azithromycin, antivirals
* Gordon, 2021	UK	multi- centre	Adaptive RCT	400mg IV	400mg IV within 24h of ICU admission with respiratory failure		corticosteroids, remdesivir

Gremese, 2020	Italy	single centre	Prospective	400mg IV	respiratory failure and radiological infiltrates	ventilatory requirement, discharge from ICU, mortality	hydroxychloroquine, azithromycin, antivirals
Sinha, 2020	USA	single centre	Prospective	200mg IV	respiratory failure and hyperinflammation	mortality, discharge from hospital, IMV	hydroxychloroquine, azithromycin
SILTUXIMAB							
*Gritti 2020	Italy	single centre	Prospective with control	11mg/kg IV. Second dose 72 hours later (n=6)	respiratory failure requiring IVM or non-IVM support	mortality, time to IVM, laboratory biomarkers	antivirals, hydroxychloroquine corticosteroids
TOCILIZUMAB							
Albertini, 2020	France	single centre	Prospective with control	8mg/kg IV. Second dose 72 hours later (n=20)	respiratory failure, bilateral radiological infiltrates, elevated CRP	respiratory rate, oxygen requirements, laboratory biomarkers	hydroxychloroquine and azithromycin
Antony, 2020	USA	multi- centre	Prospective	4mg/kg/day IV 12 hourly	supplemental oxygen dose >3L/min, but not mechanically ventilated	mortality, ventilatory requirement, laboratory biomarkers	methylprednisolone
Campins, 2020	Spain	single centre	Prospective	N/R	N/R	mortality	corticosteroids (98%)
*Carvalho, 2020	Brazil	single centre	Prospective with control	400mg IV two doses	respiratory failure, hyperinflammation	in-hospital mortality, need for renal replacement therapy, inflammatory and oxygenation markers, use of antibiotics	hydroxychloroquine, azithromycin
Dastan, 2020	Iran	single centre	Prospective	400mg IV	severe: respiratory failure, or bilateral radiological infiltrates, IL-6>10pg/mL critical: need for ICU or IMV	oxygen requirements, ventilatory requirements, death, laboratory biomarkers	antivirals
* Gordon, 2021	UK	multi- centre	Adaptive RCT	8mg/kg IV repeated after 12-24h	within 24h of ICU admission with respiratory failure	respiratory and cardiovascular organ support-free days up to day 21, mortality, time to discharge	corticosteroids, remdesivir

Hermine, 2020	France	multi- centre	Open label RCT	8mg/kg IV	radiological infiltrates with respiratory failure but not admitted to ICU	dead or ventilatory support on day 4, survival at day 14, laboratory biomarkers	antivirals, corticosteroids
Malekzadeh, 2020	Iran	multi- centre	Prospective	324mg or 486mg SC (weight dependent)	respiratory failure and hyperinflammation	all-cause mortality, change on 6-point ordinal scale, laboratory biomarkers	hydroxychloroquine, antivirals, antibiotics, interferon beta
Mikulska, 2020	Italy	single centre	Prospective with control	8mg/kg IV (62%) or 162mg SC (38%). Second dose in 24%	respiratory failure	IMV, death	hydroxychloroquine, antivirals, antibiotics
Morena, 2020	Italy	single centre	Prospective	8mg/kg IV repeated after 12h	respiratory failure, IL-6 > 40pg/mL	death, hospital discharge	hydroxychloroquine, antivirals, antibiotics
Perrone 2020	Italy	multi- centre	Single arm, open- label & validation	8mg/kg/IV	respiratory failure	mortality rates at 14 and 30 days	hydroxychloroquine, antibiotics, antivirals, steroids
*Rosas, I., 2020	USA	multi- centre	Placebo-controlled, double blind, phase 3 RCT	8mg/kg IV, second dose 8- 24h later permitted	respiratory failure with bilateral radiological infiltrates	status on a 7-point ordinal scale, time to hospital/ICU discharge, time to improvement on ordinal scale, incidence of IMV	corticosteroids, antivirals, convalescent plasma
Roumier, 2020	France	single centre	Prospective with control	8mg/kg IV repeated once	respiratory failure, hyperinflammation	mortality, IMV, hospital status	Hydroxychloroquine, azithromycin, corticosteroids
Salvarani, 2020	Italy	multi- centre	Open label RCT	8mg/kg IV, repeated 12h later	respiratory failure and hyperinflammation	ICU admission and need for IMV, death, respiratory failure	hydroxychloroquine, antivirals, antibiotics
*Sanchez- Montalva, 2020	Spain	single centre	Prospective	400-600mg IV	respiratory failure, hyperinflammation	death at 7 days, admission to ICU, ARDS	Hydroxychloroquine, antibiotics, antivirals
Salama, 2020	USA	multi- centre	Double blind RCT	8mg/kg IV	respiratory failure not requiring ventilatory support	mortality, ventilatory requirement, duration of hospitalisation	Antivirals, corticosteroids
Sciascia, 2020	Italy	multi- centre	Prospective	8mg/kg IV or 324mg S/C. Second dose in 83%	respiratory failure, hyperinflammation	medication safety, oxygen requirement, laboratory biomarkers	antivirals

Stone, 2020	USA	multi- centre	Double blind RCT	8mg/kg IV	hyperinflammation with two of: fever, lung infiltrates or respiratory failure	intubation or death,	antiviral, hydroxychloroquine, corticosteroids
Strohbehn, 2020	USA	single centre	Phase 2 open label	40-200mg	bilateral radiological infiltrates, fever, CRP>40mg/L	resolution of fever, CRP reduction, overall survival at 28 days, rate and duration of IMV, duration of supplemental oxygen	hydroxychloroquine, azithromycin, antiviral
Toniati, 2020	Italy	single centre	Prospective	8mg/kg IV, repeated after 12h (87%). Third dose 24h later (13%)	respiratory failure requiring ventilatory support	ventilatory requirements, discharge, death	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Biran, 2020	USA	multi- centre	Retrospective	400mg IV with 12% receiving a second dose	hospitalised requiring ICU stay	mortality, inflammatory biomarkers, oxygenation, infection, use of vasopressors	corticosteroids, hydroxychloroquine, azithromycin
Canziani, 2020	Italy	multi- centre	Retrospective	8mg/kg IV followed by a second dose 24h later (95%)	respiratory failure, elevated CRP, absence of active bacterial infection	mortality, incidence of invasive ventilation, thromboembolic events, haemorrhagic event, infections	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Capra, 2020	Italy	single centre	Retrospective	400mg IV (53%); 324mg SC (44%)	tachypnoea or hypoxia. IMV patients excluded	overall mortality	hydroxychloroquine, antivirals
Chillmuri, 2020	USA	single centre	Retrospective	400mg IV	respiratory failure and hyperinflammation	ventilatory requirement, mortality	hydroxychloroquine, antivirals, corticosteroids
De Rossi, 2020	Italy	single centre	Retrospective	400mg IV (48%); 324mg SC (52%)	respiratory failure, bilateral radiological infiltrates. IMV patients excluded	overall mortality	hydroxychloroquine, antivirals
Eimer, 2020	Sweden	single centre	Retrospective	8mg/kg IV	respiratory failure admitted to intensive care, with hyperinflammation	30-day mortality, time to extubation, ventilator free-days, length of hospital and ICU stay	Nil
Fisher, 2020	USA	single centre	Retrospective	400mg IV, repeated after 24h	respiratory failure	30 day mortality	hydroxychloroquine, steroids

Galvan Roman, 2020	Spain	single centre	Retrospective	8mg/kg/IV, repeated after 12h	respiratory failure, hyperinflammation,	mortality, IL-6 levels, mechanical ventilation,	hydroxychloroquine, antivirals, antibiotics, corticosteroids
*Garcia, 2020	Spain	single centre	Retrospective	400-600mg IV repeated 12h apart with up to 3 doses	radiological infiltrates, respiratory failure and hyperinflammation	ICU admission and need for IMV	hydroxychloroquine, antivirals, azithromycin
Gokhale, 2020	India	single centre	Retrospective	400mg IV	respiratory failure, bilateral 400mg IV radiological infiltrates, hyperinflammation		hydroxychloroquine, antivirals, antibiotics, corticosteroids
Guaraldi, 2020	Italy	multi- centre	Retrospective	8mg/kg IV, repeated after 12h, or 324mg SC single dose	respiratory failure, lung infiltrates >50%	IMV or death	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Guisado-Vasco, 2020	Spain	single centre	Retrospective	8mg/kg/IV	radiological infiltrates and respiratory failure	hospital mortality, length of hospitalisation, admission to ICU, requirement for IMV	hydroxychloroquine, antivirals, corticosteroids
Gupta, 2020	USA	multi- centre	Retrospective	Treated in first 2 days, dose not specified	admitted to ICU	hospital mortality, secondary infections	hydroxychloroquine, azithromycin, corticosteroids
Hill, 2020	USA	single centre	Retrospective	400mg IV, repeated in 3 patients after 24h	fever with either respiratory failure, haemodynamic instability, or serum IL-6 >5 times upper limit of normal	clinical improvement (two-point reduction on six-point scale), mortality within 28 days	hydroxychloroquine, remdesivir
Holt, 2020	USA	single centre	Retrospective	400mg IV	respiratory failure and hyperinflammation	mortality	N/R
lp, 2020	USA	multi- centre	Retrospective	400mg IV	hospitalised on ICU	overall mortality	hydroxychloroquine, azithromycin, corticosteroids
Kewan, 2020	USA	single centre	Retrospective	8mg/kg IV	respiratory failure, lung infiltrates, hyperinflammation	Time to clinical improvement, duration of IMV, duration of vasopressor support	hydroxychloroquine, azithromycin, corticosteroids
Kimmig, 2020	USA	single centre	Retrospective	400mg IV	clinical deterioration with hyperinflammation	mortality, infection rate	N/R
Klopfenstein, 2020	France	single centre	Retrospective	N/R	respiratory failure, >25% lung infiltrates, hyperinflammation	death and/or ICU admission	hydroxychloroquine, antivirals, antibiotics, corticosteroids

Lewis, 2020	USA	multi- centre	Retrospective	400mg IV	respiratory failure and hyperinflammation	mortality, duration of hospitalisation	azithromycin, corticosteroids
Martinez-Sanz, 2020	Spain	multi- centre	Retrospective	600-800mg	hospitalised	time to death or intensive care unit admission	hydroxychloroquine, antivirals, antibiotics, corticosteroids
# Narain, 2020	USA	multi- centre	Retrospective	N/R	hyperinflammation	hospital mortality	hydroxychloroquine
Nasa, 2020	India	multi- centre	Retrospective	8mg/kg IV, repeated after 12 hours	respiratory failure with hyperinflammation	mortality at day 28	hydroxychloroquine, antivirals corticosteroids
Patel, 2020	USA	single centre	Retrospective	N/R	severe: respiratory failure critical: requiring IMV	overall mortality, hospital discharge, inflammatory biomarkers	hydroxychloroquine, antivirals corticosteroids
* Petrak, 2020	USA	multi- centre	Retrospective	N/R	N/R IMV		hydroxychloroquine, antivirals antibiotics, corticosteroids
Pettit, 2020	USA	single centre	Retrospective	400mg IV	400mg IV respiratory failure with hyperinflammation		hydroxychloroquine and remdesivir
Potere, 2020	Italy	single centre	Retrospective	324mg SC	hyperinflammation with no hypoxaemia	disease progression, inflammatory biomarkers	hydroxychloroquine, antivirals corticosteroids
*Ramaswamy, 2020	USA	multi- centre	Retrospective	400mg IV, 8mg/kg	respiratory failure, hyperinflammation	inpatient mortality	hydroxychloroquine, azithromycin, corticosteroids
Rodriguez- Bano, 2020	Spain	multi- centre	Retrospective	N/R	hyperinflammation. IMV patients excluded	intubation, death, secondary bacterial infections, scores on a seven-point ordinal scale	hydroxychloroquine, antivirals antibiotics, interferon beta
Rojas-Marte, 2020	USA	single centre	Retrospective	N/R	respiratory failure	overall mortality rate	hydroxychloroquine, antivirals antibiotics, corticosteroids
Roomi, 2020	USA	single centre	Retrospective	N/R	hospitalised	overall mortality, IMV	hydroxychloroquine, corticosteroids
Rosas, J., 2020	Spain	single centre	Retrospective	400/600mg IV	radiological infiltrates and respiratory failure	admission to ICU, hospital discharge, mortality	hydroxychloroquine, antivirals antibiotics, corticosteroids

Rossi, 2020	France	single centre	Retrospective	400mg IV	respiratory failure. IMV patients excluded	composite of all-cause mortality and invasive ventilation	hydroxychloroquine, antivirals, corticosteroids
Rossotti, 2020	Italy	single centre	Retrospective	8mg/kg IV repeated 12h later if ongoing fever	respiratory failure, bilateral radiological infiltrates, hyperinflammation	overall survival	hydroxychloroquine, antivirals
Ruiz-Antoran, 2020	Spain	multi- centre	Retrospective	400-600mg IV repeated up to three doses	respiratory failure, hyperinflammation	in-hospital mortality	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Somers, 2020	USA	single centre	Retrospective	8mg/kg IV	IMV	survival probability, ordinal scale at day 28	hydroxychloroquine, corticosteroids
Tian, 2020	China	multi- centre	Retrospective	4-8mg/kg IV repeated after 12h if ongoing fever	respiratory failure and hyperinflammation	mortality, time from admission to discharge	antivirals, antibiotics, corticosteroids
Tsai, 2020	USA	single centre	Retrospective	400-800mg IV	respiratory failure and ferritin >300ug/mL	overall mortality	hydroxychloroquine, azithromycin
* Wadud, 2020	USA	single centre	Retrospective	N/R	hospitalised	mortality, discharge, number of days on ventilator, in ICU and in hospital	N/R
Zheng, 2020	China	single centre	Retrospective	400mg IV, repeat after 24h if persistent fever	severe: respiratory failure critical: shock	mortality, discharge, inflammatory biomarkers	Nil

Supplementary Table 1 – Methodological characteristics of included studies. Age in years reported as mean (standard deviation) unless otherwise stated.

ARDS, acute respiratory distress syndrome; CPAP, continuous positive airways pressure; CRP, C reactive protein; ICU, intensive care unit; IL6, interleukin 6; IV, intravenous; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; N/R, not reported; SC, subcutaneous; SOFA, sequential organ failure assessment; suPAR, soluble urokinase plasminogen activator receptor. * non peer-reviewed preprint study; #, study investigating both anakinra and tocilizumab

Author, year	Study design	N Treatment/ Control	Follow up, days	Control Age	Intervention Age	Sex (male control) %	Sex (male) intervention %	Outcomes
						ANAKINRA		
Balkhair, 2020	Prospective with control	45/24	N/R	51.7 (14.8) ^a	49.8 (16) ª	71	78	IMV occurred in 31% in the anakinra group and 75% in the control (p < 0.001). Death occurred in 29% in the anakinra group and 46% in the control (p = 0.082).
Huet, 2020	Prospective with control	52/44	N/R	71 (15) ª	71 (13) ª	57	69	IMV or death in anakinra group vs control HR 0.22; 95% CI 0.1-0.49. For death alone: HR 0·30; 95% CI 0·12–0·71. Decrease in CRP vs control group.
Kooistra, 2020	Prospective with control	21/39	28	67 (59-72) °	63 (55-71) ^c	85	67	No difference between anakinra and control group in time on IMV (23 vs 17 days; p=0.79), length of ICU stay (24 days vs 17; p=0.59), 28 day mortality (19% vs 18%; p=087)
*Kyriazopoul ou, 2020	Prospective	130/130	30	63.5 (13.7)	63.2 (14.1)	65	62	severe respiratory failure lower in anakinra treated group (22.3% vs 59.2%), and lower 30-day mortality (aHR 0.49, 95%CI 0.25-0.97).
Cauchois, 2020	Retrospective	12/10	N/R	N/R	N/R	N/R	N/R	Fewer no. days with oxygen < 3L/min in anakinra group vs control at day 20 (p<0.05). No. of days without IMV similar. Rapid reduction of CRP with anakinra vs. controls (p<0.001)
Cavalli, 2020	Retrospective	29/16	21	70 (64-78) ^c	63 (51-73) ^c	88	83	Control: Survival at 21 days of 56%. Mechanical ventilation-free surviva 50%. Tocilizumab high dose: Survival of 90% at 21 day (p=0.009 vs control group). IMV-free survival 72% (p=0.15 vs control group)
# Narain, 2020	Retrospective	57/3076	N/R	65 (54-77) ^c	67 (58-75) ^c	62	67	No effect on mortality (aHR 0.79; 95% CI 0.44-1.42)
					s	ARILUMAB		
Benucci, 2020	Prospective	8/0	14	-	62	-	75	87% discharged within 14 days.

Della-Torre, 2020	Prospective with control	28/28	28	57 (52-60) ^c	56 (49-60) ^c	71	85	Survival similar in both groups (HR 0.36; 95% CI 0.08-1.68). In treatmen group, median time to death higher (19 vs. 4 days; p=0.006), median time to CRP normalisation lower (6 vs. 12 days; p<0.0001). Median time to clinical improvement, discharge and IMV free survival similar. Media time to clinical improvement shorter in patients with a baseline PaO2/FiO2 >100mgHg (7 vs 28 days; HR 0.18; 95% CI 0.02-0.26)
* Gordon, 2021	Adaptive RCT	45/397	NR	61.1 (12.8) ^a	63.4 (13.4) ^a	70	81	Mean adjusted odds ratio for survival was 2.01 (95%CI 1.18-2.71). Compared with control, median adjusted odds ratios for organ support free days was 1.76 (95%CI 1.17-2.91). Sarilumab associated with improved time to ICU discharge (aHR 1.64; 95%CI 1.21-2.45), improved time to hospital discharge (aHR 1.6; 95%CI 1.17-2.40), improved ordina scale outcomes at day 14 (aOR 1.86; 95%CI 1.22-2.91).
Gremese, 2020	Prospective	53/0	16 (14-24) ^b	-	66 (40-95) ^c	-	89	83% (89.7% in medical wards and 64.3% in ICU) improved on therapy. Overall mortality of 5.7%
Sinha, 2020	Prospective	255/0	N/R	-	59 (47-70) °	-	63	10.9% of patients died. Mortality was lower in patients with FiO2 < 0.4 (HR 0.24; 95% CI 0.08-0.74)
					SI	LTUXIMAB		
* Gritti 2020	Prospective with control	30/30	33.3 (7-58) ^b	65 (56-70) b	64 (57-66) ^b	80	77	30-day mortality lower in treatment arm (HR 0.46; 95% CI 0.22-0.97). 53% recovered and were discharged.
					то	CILIZUMAB		
Albertini, 2020	Prospective with control	22/22	14	65 (41-82) b	64 (41-80) ^b	68	73	average respiratory rate at d14 lower in treated (21.5 vs 25.5 breaths/min; 95% CI -7.5 to -0.4). No difference in requirement for intubation. Significant fall in CRP in treated patients on d7 (p=0.04)
Antony, 2020	Prospective	80/0	N/R	-	63 (51-72) ^b	-	57	8.8% of patients died and 11.3% required mechanical ventilation. CRP levels reduced post therapy, whereas IL-6 increased

Campins, 2020	Prospective	58/0	N/R	-	60.6	-	72	32.4% of patients were admitted to intensive care, 13.8% died. No difference in median CRP and IL-6 between survivors and dead
* Carvalho, 2020	Prospective with control	29/24	14	59 (51-72) ^c	55 (44-65) ^c	75	62	Tocilizumab not associated with mortality (HR 3.97; 95% CI 0.28-5.72), or positive cultures (OR 1.73; 95% CI 0.22-13.82)
Dastan, 2020	Prospective	42/0	28	-	56 (44-61) ^c	-	64	14% required IMV, remaining patients showed clinical improvement. B d28, 16.7% of patients died
* Gordon, 2021	Adaptive RCT	350/397	NR	61.1 (12.8) ^a	61.5 (12.5) ^a	70	74	Mean adjusted odds ratio for survival was 1.64 (95%CI 1.14-2.35). Compared with control, median adjusted odds ratios for organ support free days was 1.64 (95%CI 1.25-2.14). Tocilizumab associated with improved time to ICU discharge (aHR 1.42; 95%CI 1.18-1.70), improved time to hospital discharge (aHR 1.41; 95%CI 1.18-1.70), improved ordinal scale outcomes at day 14 (aOR 1.83; 95%CI 1.40-2.41).
Hermine, 2020	Open label RCT	64/67	90	63 (57-72) ^c	64 (57-74) ^c	66	70	At day 14, fewer patients died or needed ventilation compared with controls (aHR 0.58; 90% CI 0.30-1.09). At day 28, mortality was similar in both groups (aHR 0.92; 95%CI 0.33-2.53)
Malekzadeh, 2020	Prospective	126/0	14	-	54 (13) ^a	-	64	By day 14, 4.7% (4/86) of severe patients and 50% (20/40) of critical patients died. By the end, 7% (6/86) of severe patients and 60% (24/40 of critical patients died.
Mikulska, 2020	Prospective with control	29/66	53 (4-70) ^b	68 (13) ª	66 (10) ^a	67	83	14-day mortality was 13.8% vs. 21.8% in control group. Mortality at study end lower in treatment group (HR 0.48; 95% CI 0.23-0.99)
Morena, 2020	Prospective	51/0	30	N/A	60 (50-70) ^c	N/A	78	Over a median follow up of 34 days, 67% of patients showed an improvement in clinical severity. Overall mortality rate was 27%
Perrone, 2020	Single-arm, open-label phase 2 trial	180/121	30	≤60: 36% 61-70: 33% ≥71: 31%	≤60: 44% 61-70: 37% ≥71: 19%	77	83	Pre-specified expected lethality rates defined as 20% and 35% at 14 and 30 days respectively. Lethality rates were 18.4% (95% Cl 13.6-24.0, p=0.52) and 22.4% (95% Cl 17.2-28.3, p<0.001) at 14 and 30 days. In tocilizumab group alone, lethality rates were 15.6% and 20%.
Perrone, 2020	Prospective with control	528/360	30	≤60: 43% 61-70: 30% ≥71: 27%	≤60: 40% 61-70: 28% ≥71: 32%	77	83	In the validation cohort, lethality rates were consistently lower than th predefined null hypothesis both at 14 and 30 days in the overall cohor (11.4% and 18.4%) and in the tocilizumab only group (10.9% and 20.0%)

* Rosas, I., 2020	Placebo- controlled, double phase 3 RCT	294/144	60	61 (14) ^a	61	70	70	No improvement in clinical status at day 28 (p=0.36), or mortality. Ordinal scale values similar (OR 1.19; 95% CI 0.81-1.76). Median time to hospital discharge shorter with tocilizumab than placebo (20 and 28 days; HR 1.35 95% CI 1.02-1.79). Median duration of ICU stay shorter with tocilizumab (9.8 and 15.5 respectively, p=0.045). Median time to improvement from baseline in 2 or more categories on ordinal scale was 14 days (12-17) in tocilizumab arm and 18 (15-28) days in placebo (p=0.08). Incidence of IMV was 27.9% in tocilizumab arm and 36.7% in placebo (p=0.14)
Roumier, 2020	Prospective with control	49/47	28	62 (13) ^a	58 (12) ^a	81	82	Tocilizumab reduced requirement for IMV (aHR 0.58; 95% CI 0.36-0.94) No difference in mortality (aHR 0.68; 95% CI 0.31-1.75)
Salama, 2020	Double-blind RCT	249/128	60	55.6 (14.9)°	56 (14.3) a	57	60	IMV or death at day 28 was lower in tocilizumab group (aHR 0.56; 95% CI 0.33 - 0.97). Mortality similar in both groups (10.4% vs 8.6%).
Salvarani, 2020	Open label RCT	60/63	30	60 (54-69) ^c	62 (52-74) ^c	56	67	28% in the tocilizumab arm and 27% in SOC group showed clinical worsening within 14 days (RR, 1.05; 95% CI, 0.59-1.86). Mortality at 14 days and at 30 days (was comparable in the 2 groups
* Sanchez- Montalva, 2020	Prospective	82/0	N/R	-	59 (20) ²	-	63	Mortality at 7 days was 26.8%. ARDS developed in 54.9%
Sciascia, 2020	Prospective	63/0	14	-	63 (13) ª	-	88	Tocilizumab associated with increased survival (HR 2.2; 95% CI 1.3-6.7). Overall mortality was 11%
Stone, 2020	Double blind RCT	161/82	28	57 (45-70) ^c	62 (46-70) ^c	55	60	HR for intubation or death compared with placebo was 0.83;95% CI, 0.38 to 1.81. At 14 days, 18.0% in tocilizumab and 14.9% in of placebo had disease progression. At 14 days, 24.6% of tocilizumab group and 21.2% of placebo were receiving supplemental oxygen.
Strohbehn, 2020	Phase 2 open label trial with control	32/41	28	68 (58-78) ^c	69 (41-73) ^c	59	50	At 24 hours, 75% of tocilizumab vs 34.1% of control were afebrile (p=0.001). 86.2% of tocilizumab vs. 14.3% control achieved CRP decrease of at least 25% (p<0.001). Median time to recovery was 3 days (IQR 2-5)

Toniati, 2020	Prospective	100/0	10	-	62 (57-71) ^c	-	88	Overall at 10 days 77% of patients improved or stabilised and 23% worsened. Mortality was 20%
Biran, 2020	Retrospective	210/420	22 (11-53) ^c	65 (56-74) ^c	62 (53-71) ^c	67	74	Exposure to tocilizumab was associated with lower hospital mortality (HR 0.64; 95% CI 0.47-0.87). In subgroup analyses, tocilizumab associated with decreased hospital mortality in those with a CRP≥150mg/L (HR 0.48;95% CI 0.3-0.77), but not in those with CRP>150mg/L (HR 0.92;95% CI 0.57-1.48).
Canziani, 2020	Retrospective	64/64	N/R	64 (8) ^a	63 (12) ^a	73	73	30-day mortality unaffected (aHR 0.82; 95% CI 0.42-1.58). Between day 6 and 30, HR 0.41 (95% CI 0.17-0.96) for tocilizumab vs controls. Tocilizumab associated with lower risk of IMV (HR 0.36; 95% CI 0.16- 0.83). No effect on thrombotic events, bleeding, infection
Capra, 2020	Retrospective	62/23	28	70 (55-80) ^c	63 (54-73) ^c	83	73	Tocilizumab associated with reduced risk of mortality (HR 0.035; 95% C 0.004-0.347)
Chillmuri, 2020	Retrospective	83/685	N/R	63 (54-73) ^c	60 (50-70) ^c	61	74	Tocilizumab associated with lower composite endpoint of IMV or death (aHR 0.29; 95% CI 0.16-0.54)
De Rossi, 2020	Retrospective	90/68	N/R	71 (15) ª	63 (13) ^a	72	71	Tocilizumab group associated with reduced risk of mortality (aHR 0.057 95% CI 0.017-0.187). Survival rate or mean time to discharge did not differ between two administration (IV and SC) routes.
Eimer, 2020	Retrospective	22/22	30	60 (54-67) ^c	61 (49-64) ^c	77	96	No difference in all-cause mortality at 30 days (HR 0.52; 95% CI 0.19-1.39). Median time to death was 8 days in treated (IQR 5-12.5) and 14 days (IQR 10-19, p = 0.15) in control. In tocilizumab group, significantly more ventilator free days. Freedom from IMV was achieved earlier and in a higher proportion of patients (HR 2.83; 95% CI 1.48-5.4). Length of hospital stay shorter in tocilizumab group
Fisher, 2020	Retrospective	45/70	30	60.6 (13.4) ^a	56.2 (14.7) a	73	64	No difference in mortality associated with tocilizumab (OR 1.04, 95% C.I. $0.27-3.75$)
Galvan Roman, 2020	Retrospective	58/88	61 (58-64) ^c	64 (54-72) ^b	61 (54-70) ^c	65	69	patients with high IL-6 not treated with TCZ showed high 139 mortality (HR: 4.6; p=0.003), as well as those with low IL-6 treated with tocilizumab (HR: 3.6; p=0.016).

* Garcia, 2020	Retrospective	77/94	14.7 (10.6) ^a	61 (16) ^a	62 (12) ^a	63	69	Tocilizumab associated with fewer ICU admissions (10.3% vs. 27.6%; p=0.005) and need for IMV (0 vs 13.8%, OR 0.03, 95% CI 0.007-0.1)
Gokhale, 2020	Retrospective	70/91	31 (12-48) °	55 (48-65) ^c	52 (44-57) ^c	58	67	Tocilizumab associated with reduced mortality (HR 0.616;95% CI 0.38-0.99)
Guaraldi, 2020	Retrospective	179/365	12 (6-17)	69 (57-78) ^c	64 (54-72) ^c	64	71	Tocilizumab use associated with reduced risk of death (7% vs. 20%; aHF 0.38; 95% CI 0.17-0.83) and composite outcome of IMV or death (aHR 0.61;95% CI 0.4-0.92).
Guisado- Vasco, 2020	Retrospective	132/475	N/R	N/R	69 (22) ^c	N/R	65	Increased mortality with tocilizumab (aOR 2·4, 95% CI, 1·13 - 5·11)
Gupta, 2020	Retrospective	433/3492	26 (15- 38) °	63 (52-72) ^c	58 (48-65) °	62	69	Patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92)
Hill, 2020	Retrospective	43/45	28	N/R	N/R	69	70	Tocilizumab not associated with lower risk of mortality (aHR 0.57; 95% CI 0.21-1.52) or a difference in clinical improvement (aHR 0.92; 95% CI 0.38-2.22)
Holt, 2020	Retrospective	24/30	N/R	N/R	N/R	N/R	N/R	In multivariate analysis, tocilizumab administration had no effect on mortality (OR 0.32; 95% CI 0.02-3.69)
lp, 2020	Retrospective	134/413	N/R	69 (58-77) °	62 (533-70) °	62	74	Tocilizumab associated with reduced mortality within the ICU setting (aHR 0.76; 95% CI 0.57-1.00)
Kewan, 2020	Retrospective	28/23	10 (6-17) c	70 (55-75) ^c	62 (53-71) ^c	48	71	Median time to clinical improvement in tocilizumab vs. no tocilizumab was 6.5 days (IQR 4-9) vs. 7 days (IQR 5-10) among all patients (HR 1.14, 95% CI 0.55-2.38). Shorter median length of hospital stay with tocilizumab. The median duration of vasopressor support and IMV were 2 days (IQR: 1·75 – 4·25 days) vs. 5 days (IQR: 4 – 8 days), p = 0.039, and 7 days (IQR: 4 – 14 days) vs. 10 days (IQR: 5 – 15 days) in tocilizumab vs. no tocilizumab cohorts, p = 0.11
Kimmig, 2020	Retrospective	54/57	N/R	62 (17) ^a	65 (14) ^a	44	69	Tocilizumab was associated with higher risk of mortality (35.2% vs 19.3%, p=0.02)

Retrospective	20/25	N/R	71 (15) ª	77 (11) ª	N/R	N/R	Death and/or ICU admissions higher in tocilizumab cohort vs control (72% vs 25%; p=0.002). No difference in death alone (25% vs 48%; p=0.0066)
Retrospective	497/497	N/R	64 (52-76) ^c	61 (52-69) ^c	58	71	Tocilizumab associated with improved survival (aHR 0.24; 95% CI 0.18-0.33). Similar time to hospital discharge (aHR 0.86; 95% CI 0.78-1.17)
Retrospective	260/969	6 (3-9) ^c	68 (57-80) ^c	65 (55-76)°	59	73	In patients with CRP>150mg/L, tocilizumab associated with decreased risk of death (aHR 0.34; 95% CI 0.16-0.72) and ICU admission or death (aHR 0.38; 95% CI 0.19-0.81), but not in those with CRP <150mg/L. For all patients, tocilizumab not associated with risk of death (HR 0.77; 95% CI 0.48-1.22)
Retrospective	73/3076	N/R	65 (54-77) ^c	62 (55-69) ^c	65	71	No effect on mortality (aHR 0.79; 95% CI 0.47-1.32)
Retrospective	22/63	N/R	52 ª	51ª	95	100	mortality at day 7 and 28 was significantly lower in the tocilizumab group (p = 0.007 and p = 0.001 respectively).
Retrospective	42/41	19 (5.5) ^c	67 (20-91) b	68 (25-96) ^b	49	50	CRP improved in all tocilizumab patients. No difference in mortality with tocilizumab but more patients discharged compared with controls (55% vs 24%)
Retrospective	81/37	N/R	62.3 (12.9)ª	56.3 (12.7) a	57	67	No difference between tocilizumab and mortality (aOR 0.83; 95%Cl 0.34-1.98). However early therapy was associated with reduced mortality (aOR 0.15; 95%Cl 0.04-0.5)
Retrospective	74/74	58	65 (16) ^a	66 (14) ^a	45	58	Mortality rate higher in tocilizumab cohort (39% vs 23%; p=0.03).
Retrospective	10/10	N/R	56 (49-60) ^c	55 (54-60) ^c	60	60	Tocilizumab associated with reduction in CRP over three days. None of the tocilizumab patients had disease progression (requirement of oxygen or mechanical ventilation) whereas progression occurred in 50% of control group
Retrospective	21/65	N/R	64 (16) ^a	63 (16) ^a	55	62	Mortality lower in tocilizumab group (HR 0.25; 95% CI 0.07-0.9)
	Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective	Retrospective 497/497 Retrospective 260/969 Retrospective 73/3076 Retrospective 22/63 Retrospective 42/41 Retrospective 81/37 Retrospective 74/74 Retrospective 10/10	Retrospective 497/497 N/R Retrospective 260/969 6 (3-9) c Retrospective 73/3076 N/R Retrospective 22/63 N/R Retrospective 42/41 19 (5.5) c Retrospective 81/37 N/R Retrospective 74/74 58 Retrospective 10/10 N/R	Retrospective 497/497 N/R 64 (52-76) c Retrospective 260/969 6 (3-9) c 68 (57-80) c Retrospective 73/3076 N/R 65 (54-77) c Retrospective 22/63 N/R 52 a Retrospective 42/41 19 (5.5) c 67 (20-91) b Retrospective 81/37 N/R 62.3 (12.9) a Retrospective 74/74 58 65 (16) a Retrospective 10/10 N/R 56 (49-60) c	Retrospective 497/497 N/R 64 (52-76) c 61 (52-69) c Retrospective 260/969 6 (3-9) c 68 (57-80) c 65 (55-76) c Retrospective 73/3076 N/R 65 (54-77) c 62 (55-69) c Retrospective 22/63 N/R 52 a 51 a Retrospective 42/41 19 (5.5) c 67 (20-91) b 68 (25-96) b Retrospective 81/37 N/R 62.3 (12.9) a 56.3 (12.7) a Retrospective 74/74 58 65 (16) a 66 (14) a Retrospective 10/10 N/R 56 (49-60) c 55 (54-60) c	Retrospective 497/497 N/R 64 (52-76) c 61 (52-69) c 58 Retrospective 260/969 6 (3-9) c 68 (57-80) c 65 (55-76) c 59 Retrospective 73/3076 N/R 65 (54-77) c 62 (55-69) c 65 Retrospective 22/63 N/R 52 c 51 c 95 Retrospective 42/41 19 (5.5) c 67 (20-91) b 68 (25-96) b 49 Retrospective 81/37 N/R 62.3 (12.9) c 56.3 (12.7) c 57 Retrospective 74/74 58 65 (16) c 66 (14) c 45 Retrospective 10/10 N/R 56 (49-60) c 55 (54-60) c 60	Retrospective 497/497 N/R 64 (52-76) c 61 (52-69) c 58 71 Retrospective 260/969 6 (3-9) c 68 (57-80) c 65 (55-76) c 59 73 Retrospective 73/3076 N/R 65 (54-77) c 62 (55-69) c 65 71 Retrospective 22/63 N/R 52 a 51 a 95 100 Retrospective 42/41 19 (5.5) c 67 (20-91) b 68 (25-96) b 49 50 Retrospective 81/37 N/R 62.3 (12.9) a 56.3 (12.7) a 57 67 Retrospective 74/74 58 65 (16) a 66 (14) a 45 58 Retrospective 10/10 N/R 56 (49-60) c 55 (54-60) c 60 60

Retrospective	88/344	21	69 (59-76) ^c	66 (56-72) ^c	69	72	Tocilizumab associated with reduced risk of death (aHR 0.12; 95% CI 0.02-0.56) and reduced risk of composite outcome of intubation or death (aHR 0.32; 95% CI 0.15-0.67)
Retrospective	96/97	14.5 (8.8)	62 (14) ^a	58 (14) ^a	ª65	77	Similar mortality in both groups (52% vs 61%; p=0.09)
Retrospective	32/144	N/R	66	58	45	64	No difference in hospital mortality (aOR 0.28; 95% CI 0.05-1.4), IMV (aOR 1.2;95% CI 0.49-2.9) and hospital discharge (aOR 0.78;95% CI 0.28-2.1). Reduction in CRP levels on day 7 compared with control (21% vs 56%; OR 0.21; 95% CI 0.08-0.55
Retrospective	20/17	30	73.8 (14.8)ª	59.4 (14.5) a	65	75	Mortality was 20% in tocilizumab group and 35% in control group. Admission to ICU was 65% in tocilizumab and 0% in control
Retrospective	84/84	28	64 (17) ª	65 (13) ª	58	66	Tocilizumab associated with reduced mortality (aHR 0.42; 95% CI 0.22-0.82), and reduced composite of mortality or IMV (aHR 0.34; 95% CI 0.22-0.52)
Retrospective	74/148	N/R	59 (52-70) ^c	59 (51-71) ^c	81	82	Tocilizumab associated with reduced mortality (unadjusted HR 0.49; 95% CI 0.26-0.95), but longer hospital stay (HR 1.66; 95% CI 1.09-2.52)
Retrospective	268/238	12 (7-18)	71 14) ª	65 (12) ª	59	69	Mortality lower in patients treated with tocilizumab than controls (16.8% vs. 31.5%, aHR 0.74; 95%Cl 0.62-0.89)
Retrospective	78/76	N/R	60 (15) ^a	55 (15) ^a	64	68	Tocilizumab associated with lower risk of death (aHR 0.55; 95% CI 0.33-0.9)
Retrospective	65/130	NR	67.5 (61-75) ^c	71(63-75) ^c	63	74	Mortality lower in tocilizumab group (aHR 0.47; 95%Cl 0.25-0.9)
Retrospective	66/66	N/R	61 (16) ª	62 (14) ^a	76	70	No difference in mortality between two groups (OR 1.0;95% CI 0.465-2.151)
Retrospective	44/50	N/R	66 b	56 ^b	70	84	Lower mortality in tocilizumab group (38.6% vs. 52%; p<0.001)
	Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective	Retrospective 96/97 Retrospective 32/144 Retrospective 20/17 Retrospective 84/84 Retrospective 74/148 Retrospective 268/238 Retrospective 78/76 Retrospective 65/130 Retrospective 66/66	Retrospective 96/97 14.5 (8.8) Retrospective 32/144 N/R Retrospective 20/17 30 Retrospective 84/84 28 Retrospective 74/148 N/R Retrospective 268/238 12 (7-18) Retrospective 78/76 N/R Retrospective 65/130 NR Retrospective 66/66 N/R	Retrospective 96/97 14.5 (8.8) a 62 (14) a Retrospective 32/144 N/R 66 Retrospective 20/17 30 73.8 (14.8) a Retrospective 84/84 28 64 (17) a Retrospective 74/148 N/R 59 (52-70) c Retrospective 268/238 12 (7-18) b 71 14) a Retrospective 78/76 N/R 60 (15) a Retrospective 65/130 NR 67.5 (61-75) c Retrospective 66/66 N/R 61 (16) a	Retrospective 96/97 14.5 (8.8) a 62 (14) a 58 (14) a Retrospective 32/144 N/R 66 58 Retrospective 20/17 30 73.8 (14.8) a 59.4 (14.5) a Retrospective 84/84 28 64 (17) a 65 (13) a Retrospective 74/148 N/R 59 (52-70) c 59 (51-71) c Retrospective 268/238 12 (7-18) b 71 14) a 65 (12) a Retrospective 78/76 N/R 60 (15) a 55 (15) a Retrospective 65/130 NR 67.5 (61-75) c 71(63-75) c Retrospective 66/66 N/R 61 (16) a 62 (14) a	Retrospective 96/97 14.5 (8.8) a 62 (14) a 65 (14) a 58 (14) a a65 Retrospective 32/144 N/R 66 58 45 Retrospective 20/17 30 73.8 (14.8) a 59.4 (14.5) a 65 65 Retrospective 84/84 28 64 (17) a 65 (13) a 58 58 Retrospective 74/148 N/R 59 (52-70) a 59 (51-71) a 59 81 Retrospective 268/238 12 (7-18) a 71 14) a 65 (12) a 59 55 (15) a 64 Retrospective 78/76 N/R 60 (15) a 55 (15) a 64 Retrospective 65/130 NR 67.5 (61-75) a 71(63-75) a 63 Retrospective 66/66 N/R 61 (16) a 62 (14) a 76	Retrospective 96/97 14.5 (8.8) shows a second of the component o

Zheng, 2020	Retrospective	92/89	28 (6-62) ^b	67 (25-85) b	69 (25-87) b	53	62	Increased mortality in tocilizumab group, but significant reduction in CRP level at 1 week
-------------	---------------	-------	---------------------------	--------------	--------------	----	----	--

Supplementary Table 2 – Patient characteristics and outcomes of included studies. Absolute numbers reported for follow up days unless otherwise statement. Number of males in control and intervention group reported as percentage (%)

^a, mean and standard deviation; ^b, median and range; ^c, median and interquartile range; aHR, adjusted hazard ratio; CI, confidence interval; CRP, C-reactive protein; ICU, intensive care unit; IL6, interleukin-6; IMV, invasive mechanical ventilation; IV, intravenous; N/R, not reported; OR, odds ratio; SC, subcutaneous; -, not available; * non peer-reviewed preprint study #, study investigating both anakinra and tocilizumab

		Randomised c	ontrolled trials										
		Tocilia	zumab										
	Gordon 2021 * Hermine 2020 Rosas, I. 2020 * Salama 2020 Salvarani 2020 Stone 202												
Randomisation	Low	Low	Low	Low	Low	Low							
Intervention assignment	Low	High	Low	Low	High	Low							
Intervention adherence	Low	Some concern	Low	Low	Some concern	Low							
Missing data	Some concern	Low	Low	Low	Low	Low							
Outcome	Low	Low	Low	Low	Low	Low							
Results	Low	Low	Low	Low	Low	Low							
Overall risk of bias	Low	Some concern	Low	Low	Some concern	Low							

Supplementary Table 3(a) – Risk of bias assessment for randomised clinical trials using Cochrane risk of bias 2 tool. Risk of bias was assessed in six categories and scored as either low risk of bias, some concern, or high risk of bias, before an overall risk of bias was given to each study.

^{*} non peer-reviewed preprint study

						Pi	ospective s	tudies							
	Tocilizumab Sanchez-														
	Albertini 2020	Antony 2020	Campins 2020	Carvalho 2020 *	Dastan 2020	Malekzad eh, 2020	Mikulsa 2020	Morena 2020	Perrone 2020	Roumier, 2020	Sanchez- Motalva 2020 *	Sciascia 2020	Strohbehn 2020	Toniati 2020	
1	+	+	-	+	+	+	+	+	+	+	+	-	+	+	
2	+	+	-	+	+	+	+	+	+	+	+	+	+	+	
3	+	+	CD	CD	+	CD	+	+	+	+	+	CD	+	+	
4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
5	-	-	-	-	-	-	-	-	+	+	-	-	-	-	
6	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
7	+	-	CD	+	+	+	+	+	+	+	+	+	+	+	
8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
9	-	+	-	-	+	+	-	+	+	+	-	-	+	-	
10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
11	+	-	-	+	+	+	+	+	+	+	+	+	+	-	
12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	+	+	CD	+	+	+	+	+	+	+	+	+	+	+	
14	-	-	-	+	-	-	+	+	-	+	+	-	+	-	
Total	8	7	2	8	9	8	9	10	10	11	9	6	10	7	
Rating	Fair	Fair	Poor	Fair	Fair	Fair	Fair	Good	Good	Good	Fair	Poor	Good	Fair	

				Pros	pective studies				
			Anakinra			Sarilum	ab		Siltuximab
	Balkhair, 2020	Huet 2020	Kooistra, 2020	Kyriazopoulou, 2020 *	Benucci 2020	Della-Torre 2020	Sinha 2020	Gremese 2020	Gritti 2020 *
1	+	+	+	+	+	+	+	+	+
2	+	+	+	+	-	+	+	+	+
3	+	+	+	+	CD	+	+	+	+
4	+	+	-	+	-	+	+	+	+
5	+	+	-	+	-	-	-	-	-
6	+	+	+	+	+	+	+	+	+
7	+	CD	+	+	+	+	+	+	+
8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
9	+	+	+	+	+	+	+	+	+
10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
11	+	+	+	+	+	+	+	+	+
12	-	-	-	-	-	-	-	-	-
13	+	+	+	+	+	+	+	+	+
14	-	+	-	+	-	+	+	-	+
Total	10	10	8	10	6	10	10	9	10

Poor

Good

Good

Fair

Good

Good

Good

Rating

Good

Fair

Supplementary Table 3(b). Risk of bias assessment for prospective studies. Questions numbered in the first column. 1. Was the research question or objective in this paper clearly stated? 2. Was the study population clearly specified and defined? 3. Was the participation rate of eligible persons at least 50%? 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 5. Was a sample size justification, power description, or variance and effect estimates provided? 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 10. Was the exposure(s) assessed more than once over time? 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 12. Were the outcome assessors blinded to the exposure status of participants? 13. Was loss to follow-up after baseline 20% or less? 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

+, criteria satisfied; -, not satisfied; N/A, not applicable; CD, cannot determine; * non peer-reviewed preprint study

								R	etrospectiv	e studies								
	Tocilizumab De Galvan Guisado Guisado																	
	Biran 2020	Canziani 2020	Capra 2020	Chillmuri, 2020	De Rossi 2020	Eimer 2020	Fisher, 2020	Galvan- Roman 2020	Garcia 2020 *	Gokhale 2020	Guaraldi 2020	Guisado- Vasco 2020	Gupta 2020	Hill 2020	Holt 2020	lp 2020	Kewan 2020	Kimmig 2020
1	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+
2	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
3	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CD	+	+	+
5	+	+	+	-	+	-	+	CD	-	+	-	+	+	-	CD	+	-	CD
6	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
7	+	+	+	+	+	+	CD	CD	+	+	+	+	+	+	CD	+	+	+
8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
10	-	-	-	-	-	+	+	+	+	+	-	-	+	-	+	+	+	-
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+
Total	8	8	9	7	9	7	8	6	7	8	7	7	9	7	6	9	8	7
Rating	Fair	Fair	Good	Fair	Good	Fair	Fair	Fair	Fair	Fair	Fair	Fair	Good	Fair	Fair	Good	Fair	Fair

	Retrospective studies Tocilizumab																	
'	Pamas Poias Puiz																	
	Klopfenst ein 2020	Lewis, 2020	Martinez- Sanz 2020	Narain 2020	Nasa 2020	Patel 2020	Petrak 2020 *	Pettit 2020	Potere 2020	Ramas wamy 2020 *	Rodriguez- Bano 2020	Rojas- Marte 2020	Roomi 2020	Rosas, J.2000	Rossi 2020	Rossotti 2020	Ruiz- Antoran 2020	Somers 2020
1	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
2	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	+	+	+	+	-	+	+	+	+	+	+	+	CD	CD	+	+	+	+
5	-	+	-	+	-	-	+	+	+	+	+	CD	-	-	+	+	CD	CD
6	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
7	+	+	+	+	+	+	+	+	+	+	+	CD	CD	CD	+	+	+	CD
8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
10	-	+	-	-	-	CD	-	-	+	+	CD	CD	-	+	+	+	-	+
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	-	+	+	+	-	-	+	-	-	+	+	-	+	-	+	+	+	+
Total	6	9	7	8	5	5	8	7	8	9	8	4	4	5	9	9	7	7
Rating	Poor	Good	Fair	Fair	Poor	Poor	Fair	Fair	Fair	Good	Fair	Poor	Poor	Poor	Good	Good	Fair	Fair

			Retrospect	tive studie	es		
		Tocilizuma	b		1	Anakinra	
	Tian 2020	Tsai 2020	Wadud 2020 *	Zheng 2020	Cauchois 2020	Cavalli 2020	Narain 2020
1	+	+	-	+	+	+	+
2	+	+	-	+	+	+	+
3	-	-	-	-	-	-	-
4	+	+	+	CD	+	+	+
5	+	+	-	-	+	+	+
6	+	+	+	+	+	+	+
7	+	+	CD	CD	+	+	+
8	-	-	-	-	-	-	-
9	+	+	+	+	+	+	+
10	+	+	-	+	+	+	-
11	-	-	-	-	-	-	-
12	+	+	-	-	-	-	+
Total	9	9	3	5	8	8	8
Rating	Good	Good	Poor	Poor	Fair	Fair	Fair

Supplementary Table 3(c). Risk of bias assessment for Retrospective studies. 1. Was the research question or objective in this paper clearly stated and appropriate? 2. Was the study population clearly specified and defined? 3. Did the authors include a sample size justification? 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? 6. Were the cases clearly defined and differentiated from controls? 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? 8. Was there use of concurrent controls? 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? 11. Were the assessors of exposure/risk blinded to the case or control status of participants? 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?

+, criteria satisfied; -, not satisfied; N/A, not applicable; CD, cannot determine; * non peer-reviewed preprint study

Author, year	Study design	N Treatment/ Control	Outcome recorded (day)		c	ontrol			Int	ervention	
				Dead	Ventilated	Hospitalised	Discharged	Dead	Ventilated	Hospitalised	Discharged
ANAKINRA											
Balkhair, 2020	Prospective with control	45/24	14	2	11	5	6	5	9	6	25
Huet, 2020	Prospective with control	52/44	-	32 #	-	-	-	13 #	-	-	-
Kooistra, 2020	Prospective with control	21/39	28	7	-	-	-	4	-	-	-
*Kyriazopoulou, 2020	Prospective with control	130/130	30	16	-	-	-	6	-	-	-
Cauchois, 2020	Retrospective	12/10	15	1	1	6	2	0	0	3	9
Cavalli, 2020	Retrospective	29/16	21	7	1	1	7	3	5	8	13
Narain, 2020	Retrospective	57/3076	-	-	-	-	-	-	-	-	-
SARILUMAB											
Benucci, 2020	Prospective	8/0	14	-	-	-	-	1	0	0	7
Della-Torre, 2020	Prospective with control	28/28	28	5	2	4	17	2	4	5	17
* Gordon, 2021	Adaptive RCT	45/397	14			Adjusted C	R for improver	ment – 1.86	(95%CI 1.22-2.	91)	
Gremese, 2020	Prospective	53/0	15	-	-	-	-	2	7	25	19
Sinha, 2020	Prospective	255/0	25	-	-	-	-	28	1	9	218
SILTUXIMAB			1								
* Gritti, 2020	Prospective with cohort	30/30	15	-	-	-	-	6	11	8	5
TOCILIZUMAB											
Albertini, 2020	Prospective with control	22/22	14	0	6	14	2	1	4	16	1
Antony, 2020	Prospective	80/0	N/R	-	-	-	-	7	9	-	-
Campins, 2020	Prospective	58/0	N/R	-	-	-	-	8	-	-	-

* Carvalho, 2020	Prospective with control	29/24	14	4	-	-	-	5	-	-	-
Dastan, 2020	Prospective	42/0	15	-	-	-	-	6	6	11	19
* Gordon, 2021	Adaptive RCT	350/397	14			Adjusted (OR for improve	ment – 1.83 (95%CI 1.40-2.4	11)	
Hermine, 2020	Open label RCT	63/67	14	6	11	20	30	7	3	21	32
Malekzadeh, 2020	Prospective	126/0	14	-	-	-	-	24	9	7	86
Mikulska, 2020	Prospective with control	29/66	14	16	-	-	-	4	2	-	-
Morena, 2020	Prospective	51/0	15	-	-	-	-	14	2	35	0
Perrone, 2020	open-label phase 2 trial	180/121	14	27	-	-	-	27	-	-	-
Perrone, 2020	Prospective with control	528/360	14	45	-	-	-	56	-	-	-
* Rosas, I., 2020	phase 3 RCT	294/144	28	28	23	22	71	50	44	26	166
Roumier, 2020	Prospective with control	49/47	28	5	-	-	33	6	-	-	23
Salama, 2020	Double-blind RCT	249/128	28	11	-	-	-	26	-	-	-
Salvarani, 2020	Open label RCT	60/63	14	1	5	21	36	1	6	19	34
* Sanchez-Montalva, 2020	Prospective	82/0	7	-	-	-	-	22	14	12	34
Sciascia, 2020	Prospective	63/0	14	-	-	-	-	7	2	-	-
Stone, 2020	Double blind RCT	161/82	28	3	-	-	72	9	-	-	147
Strohbehn, 2020	Phase 2 open label	32/41	28	-	-	-	-	5	-	-	-
Toniati, 2020	Prospective	100/0	10	-	-	-	-	20	-	-	15
Biran, 2020	Retrospective	210/420	N/R	-	-	-	-	102	-	-	135
Canziani, 2020	Retrospective	64/64	N/R	24	-	-	-	17	-	-	-
Capra, 2020	Retrospective	62/23	9	11	4	0	8	2	5	32	23
Chillmuri, 2020	Retrospective	83/685	N/R	-	-	-	-	-	-	-	-
De Rossi, 2020	Retrospective	90/68	N/R	34	6	-	-	7	13	-	-
Eimer, 2020	Retrospective	22/22	30	7	5	7	3	5	1	4	12

Fisher, 2020	Retrospective	45/70	30	28	-	-	-	13	-	-	-
Galvan Roman, 2020	Retrospective	58/88	61	16	-	-	-	14	-	-	-
* Garcia, 2020	Retrospective	77/94	14	-	-	-	71	-	-	-	65
Gokhale, 2020	Retrospective	70/91	N/R	61	-	-	30	33	2	9	26
Guaraldi, 2020	Retrospective	179/365	14	60	117	-	-	9	42	-	-
Guisado-Vasco, 2020	Retrospective	132/475	N/R	97	-	-	-	44	-	-	-
Gupta, 2020	Retrospective	433/3492	27	1419	-	-	-	125	-	-	-
Hill, 2020	Retrospective	43/45	28	15	0	3	27	9	6	2	26
Holt, 2020	Retrospective	24/30	N/R	-	-	-	-	-	-	-	-
lp, 2020	Retrospective	134/413	30	231	-	-	-	62	-	-	-
Kewan, 2020	Retrospective	28/23	14	2	7	4	10	3	10	5	10
Kimmig, 2020	Retrospective	54/57	N/R	11	-	-	34	19	-	-	18
Klopfenstein, 2020	Retrospective	20/25	N/R	12	-	-	11	5	-	-	11
Lewis, 2020	Retrospective	497/497	N/R	211	-	-	283	145	-	-	332
Martinez-Sanz, 2020	Retrospective	260/969	N/R	120	-	-	-	61	-	-	-
Narain, 2020	Retrospective	73/3076	N/R	-	-	-	-	-	-	-	-
Nasa, 2020	Retrospective	22/63	28	36	-	-	-	2	-	-	-
Patel, 2020	Retrospective	42/41	7	11	-	7	7	9	-		7
* Petrak, 2020	Retrospective	81/37	N/R	-	-	-	-	-	-	-	-
Pettit, 2020	Retrospective	74/74	N/R	17	-	-	-	29	-	-	-
Potere, 2020	Retrospective	10/10	14	0	1	4	5	0	0	2	8
* Ramaswamy, 2020	Retrospective	21/65	N/R	8	-	-	-	3	-	-	-
Rodriguez-Bano, 2020	Retrospective	88/344	21	41	20	30	253	2	6	10	70
Rojas-Marte, 2020	Retrospective	96/97	N/R	55	-	-	-	43	-	-	
Roomi, 2020	Retrospective	32/144	N/R	13	-	-	38	6	-	-	25
Rosas, J., 2020	Retrospective	20/17	30	6	-	-	-	4	-	-	-
Rossi, 2020	Retrospective	84/84	N/R	-	-	-	-	-	-	-	-
Rossotti, 2020	Retrospective	74/148	NR	-	-	-	-	8	18	45	14
Ruiz-Antoran, 2020	Retrospective	268/238	N/R	75	-	-	-	45	-	-	-
Somers, 2020	Retrospective	78/76	14	28	15	11	22	14	21	12	31
Tian, 2020	Retrospective	65/130	N/R	42	-	-	-	14	-	-	-
Tsai, 2020	Retrospective	66/66	N/R	18	-	-	-	18	-	-	-

* Wadud, 2020	Retrospective	44/50	N/R	26	-	-	-	17	-	-	-
Zheng, 2020	Retrospective	92/89	27.5	1	0	0	88	9	0	0	83

Supplementary Table 4 – Primary clinical outcome. Outcome scores presenting using absolute scores with number of individuals in each category, using adapted ordinal outcome scores 1 indicates death, 2 described hospitalised patients requiring invasive ventilatory support, 3 describes patients not requiring invasive ventilatory support but still hospitalised, 4 describes discharged patients. Day outcomes reported shown where applicable.

^{*} non peer-reviewed preprint study, CI, confidence interval # death or ventilation

			Re	etrospective studies						
Variables	Generalise	d odds ratios for	Difference	in duration of	Adjusted ha	zard ratios for	Risk ratios for mortality (N=			
	ordinal outcomes (N=10)		hospitalis	ation (N=9)	mortali	ty (N=18)				
	R ²	P value	R ²	P value	R ²	P value	R ²	P value		
Steroid use	0.00	0.7921	7.17	0.2305	0.00	0.9710	0.00	0.5252		
Peer review	N/A	N/A	N/A	N/A	0.9	0.5638	0.00	0.4137		
Route of administration	4.75	0.3526	81.64	<0.001	0.00	0.3921	2.68	0.2053		
Single centre	0.00	0.6028	11.03	0.2013	2.96	0.4103	0.00	0.2154		
Outcome day	0.00	0.7921	N/A	N/A	99.99	0.0818	9.54	0.4141		
			Р	rospective studies						
Variables	Generalised odds ratios for		Difference	in duration of	Adjusted ha	zard ratios for	Risk ratios for mortality (N=11)			
	ordinal o	utcomes (N=5)	hospitalis	ation (N=1)	mortality (N=4)					
	R ²	P value	R ²	P value	R ²	P value	R ²	P value		
Steroid use	99.99	<0.0001	N/A	N/A	45.29	0.3464	0.00	0.9050		
Peer review	0.00	0.4890	N/A	N/A	N/A	N/A	0.00	0.5764		
Route of administration	N/A	N/A	N/A	N/A	45.29	0.3464	69.89	0.5922		
Single centre	0.00	0.5332	N/A	N/A	0.00	0.2425	0.00	0.8638		
Outcome day	0.00	0.5351	N/A	N/A	0.00	0.7187	0.00	0.6115		

Supplementary Table 5 - Results of meta-regression for variables assessed separated by study design (retrospective and prospective) and study outcomes. Study numbers for each outcome shown (N). R² and p values from meta-regression shown were applicable.

N/A, not applicable.

Outcome	The GRADE domains	Ratings for quality of evidence
	Risk of bias	Of the 4 prospective included, 3 RCTs of low/moderate risk of bias included. Retrospective studies generally of fair quality, although cannot exclude failure to control confounding factors.
	Imprecision	No serious imprecision, with appropriately narrow 95% confidence intervals. Outcome based on 1782 patients.
Ordinal scale (12 studies; 4 prospective and 8 retrospective. Total of	Inconsistency	High inconsistency with significant heterogeneity in both prospective and retrospective studies.
1782 patients)	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent.
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests
	Certainty of evidence	Moderate certainty of evidence.
	Risk of bias	All included retrospective studies with moderate/high risk of bias. Confounding factors were poorly controlled for.
Difference in duration of hospitalisation (9	Imprecision	Serious imprecision, with studies showing shorter and longer duration of hospitalisation with tocilizumab. Appropriately narrow 95% confidence intervals.
retrospective studies, 1 RCT. Total of 2285 patients)	Inconsistency	High inconsistency with significant heterogeneity ($I^2 = 93.8\%$).
	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent.
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests

	Certainty of evidence	Low certainty of evidence.
	Risk of bias	RCTs of low/moderate risk of bias included.
	Imprecision	No imprecision present
Overall mortality (aHR - 22	Inconsistency	High inconsistency in retrospective studies, but not in prospective studies.
studies. Total of 13,702 patients. RR - 42 studies, 15,085 patients)	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests
	Certainty of evidence	High certainty of evidence.

Supplementary Table 6 – GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach to rate the quality of evidence on the effects of tocilizumab